메뉴 건너뛰기




Volumn 16, Issue 3, 2004, Pages 155-166

Aripiprazole: Review of its pharmacology and therapeutic use in psychiatric disorders

Author keywords

Antipsychotics; Aripiprazole; Bipolar disorder; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; FLUDROCORTISONE; FLUOXETINE; GLUCOSE; HALOPERIDOL; LORAZEPAM; METHOTRIMEPERAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERPHENAZINE; PROPRANOLOL; QUETIAPINE; QUINIDINE; RISPERIDONE; SULPIRIDE; TERAZINE; THIORIDAZINE; UNCLASSIFIED DRUG; ZIPRASIDONE; ZUCLOPENTHIXOL;

EID: 4644250170     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1080/10401230490487007     Document Type: Article
Times cited : (47)

References (50)
  • 1
    • 0001057794 scopus 로고
    • A survey of neuroleptic-induced extrapyramidal reactions
    • Ayd FJJ: A survey of neuroleptic-induced extrapyramidal reactions. JAMA 1961; 175:1054-1061.
    • (1961) JAMA , vol.175 , pp. 1054-1061
    • Ayd, F.J.J.1
  • 4
  • 5
    • 0020054615 scopus 로고
    • Tardive dyskinesia: Prevalence and risk factors, 1959-1979
    • Kane JM, Smith JM: Tardive dyskinesia: Prevalence and risk factors, 1959-1979. Arch Gen Psychiatry 1982; 39:473-481.
    • (1982) Arch Gen Psychiatry , vol.39 , pp. 473-481
    • Kane, J.M.1    Smith, J.M.2
  • 7
    • 0026544764 scopus 로고
    • Clinical efficacy of clozapine in treatment-refractory schizophrenia: An overview
    • Kane JM: Clinical efficacy of clozapine in treatment-refractory schizophrenia: An overview. Br J Psychiatry 1992; 160(suppl.17):41-45.
    • (1992) Br J Psychiatry , vol.160 , Issue.17 SUPPL. , pp. 41-45
    • Kane, J.M.1
  • 8
    • 0026559173 scopus 로고
    • Clozapine-associated agranulocytosis: Risk and aetiology
    • Krupp P, Barnes P: Clozapine-associated agranulocytosis: Risk and aetiology. Br J Psychiatry 1992; 160 (suppl. 17):38-40.
    • (1992) Br J Psychiatry , vol.160 , Issue.17 SUPPL. , pp. 38-40
    • Krupp, P.1    Barnes, P.2
  • 9
    • 0034095251 scopus 로고    scopus 로고
    • Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol
    • The Canadian Collaborative Group for research in schizophrenia
    • Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Brier A, Tollefson GD. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Archives of General Psychiatry 2000; 57:249-258.
    • (2000) Archives of General Psychiatry , vol.57 , pp. 249-258
    • Purdon, S.E.1    Jones, B.D.2    Stip, E.3    Labelle, A.4    Addington, D.5    David, S.R.6    Brier, A.7    Tollefson, G.D.8
  • 10
    • 0031963973 scopus 로고    scopus 로고
    • Antipsychotic properties of the partial dopamine agonist (-)-3(3-hydroxy-phenyl)-N-n-propylpiperidine (preclamol) in schizophrenia
    • Lahti AC, Weiler MA, Corey PK, et al. Antipsychotic properties of the partial dopamine agonist (-)-3(3-hydroxy-phenyl)-N-n-propylpiperidine (preclamol) in schizophrenia. Biol Psychiatry 1998; 43:2-11.
    • (1998) Biol Psychiatry , vol.43 , pp. 2-11
    • Lahti, A.C.1    Weiler, M.A.2    Corey, P.K.3
  • 11
    • 0031901331 scopus 로고    scopus 로고
    • Initial safety, tolerability, pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia
    • Sramek JJ, Eldon MA, Posvar E, et al. Initial safety, tolerability, pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia. Psychopharmacol Bull 1998; 34:93-99.
    • (1998) Psychopharmacol Bull , vol.34 , pp. 93-99
    • Sramek, J.J.1    Eldon, M.A.2    Posvar, E.3
  • 12
    • 0036089687 scopus 로고    scopus 로고
    • Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors
    • Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302:381-389.
    • (2002) J Pharmacol Exp Ther , vol.302 , pp. 381-389
    • Burris, K.D.1    Molski, T.F.2    Xu, C.3
  • 13
    • 0037177358 scopus 로고    scopus 로고
    • The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
    • Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002; 441:137-140.
    • (2002) Eur J Pharmacol , vol.441 , pp. 137-140
    • Jordan, S.1    Koprivica, V.2    Chen, R.3    Tottori, K.4    Kikuchi, T.5    Altar, C.A.6
  • 15
    • 4644284333 scopus 로고    scopus 로고
    • Bristol-Myers Squibb Company, Princeton, New Jersey; November
    • Abilify™ prescribing information. Bristol-Myers Squibb Company, Princeton, New Jersey; November 2002.
    • (2002) Abilify™ Prescribing Information
  • 17
    • 0033151286 scopus 로고    scopus 로고
    • Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes
    • Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacol 1999; 20:612-627.
    • (1999) Neuropsychopharmacol , vol.20 , pp. 612-627
    • Lawler, C.P.1    Prioleau, C.2    Lewis, M.M.3
  • 18
    • 0034826997 scopus 로고    scopus 로고
    • Strategy for modulation of central dopamine transmission based on partial agonist concept in schizophrenia
    • Inoue A, Nakata Y. Strategy for modulation of central dopamine transmission based on partial agonist concept in schizophrenia. Jpn J Pharmacol 2001; 86:376-380.
    • (2001) Jpn J Pharmacol , vol.86 , pp. 376-380
    • Inoue, A.1    Nakata, Y.2
  • 19
    • 10744232425 scopus 로고    scopus 로고
    • Mechanism of action of new antipsychotic medications
    • Grunder G, Carlsson A, Wong D. Mechanism of action of new antipsychotic medications. Arch Gen Psychiatry 2003; 60:974-977.
    • (2003) Arch Gen Psychiatry , vol.60 , pp. 974-977
    • Grunder, G.1    Carlsson, A.2    Wong, D.3
  • 23
    • 1442277874 scopus 로고    scopus 로고
    • Effects of renal and hepatic impairment on the pharmacokinetics of aripiprazole
    • May 17-22, San Francisco, CA
    • Bramer S, Shoaf S, Salazar DE, Mallikaarjun S. Effects of renal and hepatic impairment on the pharmacokinetics of aripiprazole. Presented at the 2003 APA Annual Meeting, May 17-22, 2003; San Francisco, CA.
    • (2003) 2003 APA Annual Meeting
    • Bramer, S.1    Shoaf, S.2    Salazar, D.E.3    Mallikaarjun, S.4
  • 25
    • 0038488945 scopus 로고    scopus 로고
    • Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder
    • Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60:681-690.
    • (2003) Arch Gen Psychiatry , vol.60 , pp. 681-690
    • Potkin, S.G.1    Saha, A.R.2    Kujawa, M.J.3    Carson, W.H.4    Ali, M.5    Stock, E.6    Stringfellow, J.7    Ingenito, G.8    Marder, S.R.9
  • 27
    • 0036738786 scopus 로고    scopus 로고
    • Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
    • Kane JM, Carson WH, Saha A, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63:763-771.
    • (2002) J Clin Psychiatry , vol.63 , pp. 763-771
    • Kane, J.M.1    Carson, W.H.2    Saha, A.3    McQuade, R.D.4    Ingenito, G.G.5    Zimbroff, D.L.6    Ali, M.W.7
  • 28
    • 0001612909 scopus 로고    scopus 로고
    • Aripiprazole, a new atypical antipsychotic: Phase II clinical trial result
    • Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a new atypical antipsychotic: phase II clinical trial result. Eur Neuropsychopharm 1997; 7(Suppl 2):S227.
    • (1997) Eur Neuropsychopharm , vol.7 , Issue.2 SUPPL.
    • Petrie, J.L.1    Saha, A.R.2    McEvoy, J.P.3
  • 29
    • 0005122819 scopus 로고    scopus 로고
    • Meta-analysis of the efficacy of aripiprazole in schizophrenia
    • Lieberman J, Carson WH, Saha AR, et al. Meta-analysis of the efficacy of aripiprazole in schizophrenia. Int J Neuropsychopharmacol 2002; 5(Suppl 1):S186.
    • (2002) Int J Neuropsychopharmacol , vol.5 , Issue.1 SUPPL.
    • Lieberman, J.1    Carson, W.H.2    Saha, A.R.3
  • 30
    • 0000374942 scopus 로고    scopus 로고
    • Aripiprazole vs placebo in the treatment of chronic schizophrenia
    • Carson WH, Pigott TA, Saha AR, et al. Aripiprazole vs placebo in the treatment of chronic schizophrenia. Int J Neuropsychopharmacol 2002a; 5(Suppl 1):S187.
    • (2002) Int J Neuropsychopharmacol , vol.5 , Issue.1 SUPPL.
    • Carson, W.H.1    Pigott, T.A.2    Saha, A.R.3
  • 31
    • 0000649073 scopus 로고    scopus 로고
    • Aripiprazole for long-term maintenance treatment of schizophrenia
    • Kujawa M, Saha AR, Ingenito GG, et al. Aripiprazole for long-term maintenance treatment of schizophrenia. Int J Neuropsychopharmacol 2002; 5(Suppl 1):S186.
    • (2002) Int J Neuropsychopharmacol , vol.5 , Issue.1 SUPPL.
    • Kujawa, M.1    Saha, A.R.2    Ingenito, G.G.3
  • 32
    • 1442277872 scopus 로고    scopus 로고
    • Aripiprazole vs perphenazine in treatment-resistant schizophrenia
    • May 17-22, San Francisco, CA
    • Kane J, Carson W, Kujawa M, et al. Aripiprazole vs perphenazine in treatment-resistant schizophrenia. Presented at the 2003 APA Annual Meeting, May 17-22, 2003; San Francisco, CA.
    • (2003) 2003 APA Annual Meeting
    • Kane, J.1    Carson, W.2    Kujawa, M.3
  • 34
    • 0038585981 scopus 로고    scopus 로고
    • A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania
    • Keck Jr. PE, Marcus R, Tourkodimitris S et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. American Journal of Psychiatry 2003; 160:1651-1658.
    • (2003) American Journal of Psychiatry , vol.160 , pp. 1651-1658
    • Keck Jr., P.E.1    Marcus, R.2    Tourkodimitris, S.3
  • 36
  • 37
    • 2042459957 scopus 로고    scopus 로고
    • Aripiprazole vs haloperidol for maintained treatment effect in acute mania
    • May 17-22, San Francisco, CA
    • Bourin M, Auby P, Swanink R, et al. Aripiprazole vs haloperidol for maintained treatment effect in acute mania. Presented at the 2003 APA Annual Meeting, May 17-22, 2003; San Francisco, CA.
    • (2003) 2003 APA Annual Meeting
    • Bourin, M.1    Auby, P.2    Swanink, R.3
  • 38
    • 4644272448 scopus 로고    scopus 로고
    • Long-term effects of aripiprazole on the negative symptoms of schizophrenia
    • May 17-22, San Francisco, CA
    • Manos G, McQuade R, Stock E, et al. Long-term effects of aripiprazole on the negative symptoms of schizophrenia. Presented at the 2003 APA Annual Meeting, May 17-22, 2003; San Francisco, CA.
    • (2003) 2003 APA Annual Meeting
    • Manos, G.1    McQuade, R.2    Stock, E.3
  • 40
    • 0000649072 scopus 로고    scopus 로고
    • Meta-analysis of weight effects with aripiprazole
    • Jody D, Saha AR, Iwamoto T, et al. Meta-analysis of weight effects with aripiprazole. Int J Neuropsychopharmacol 2002b; 5(Suppl 1):S186.
    • (2002) Int J Neuropsychopharmacol , vol.5 , Issue.1 SUPPL.
    • Jody, D.1    Saha, A.R.2    Iwamoto, T.3
  • 41
    • 34447514978 scopus 로고    scopus 로고
    • Glycemic control and plasma lipids in long-term treatment with aripiprazole
    • May 17-22, San Francisco, CA
    • Marder SR, Jody D, Kaplita S, et al. Glycemic control and plasma lipids in long-term treatment with aripiprazole. Presented at the 2003 APA Annual Meeting, May 17-22, 2003; San Francisco, CA.
    • (2003) 2003 APA Annual Meeting
    • Marder, S.R.1    Jody, D.2    Kaplita, S.3
  • 42
    • 1442302481 scopus 로고    scopus 로고
    • Aripiprazole is not associated with increased diabetes risk: A long-term model
    • May 17-22, San Francisco, CA
    • Weiden P, Waldeck R, Tafesse E, Cislo P, L'Italien G, Carson W. Aripiprazole is not associated with increased diabetes risk: A long-term model. Presented at the 2003 APA Annual Meeting, May 17-22, 2003; San Francisco, CA.
    • (2003) 2003 APA Annual Meeting
    • Weiden, P.1    Waldeck, R.2    Tafesse, E.3    Cislo, P.4    L'Italien, G.5    Carson, W.6
  • 43
    • 1442302479 scopus 로고    scopus 로고
    • Metabolic syndrome comparison between olanzapine, aripiprazole, and placebo
    • May 17-22, San Francisco, CA
    • Casey D, L'Italien GL, Waldeck R, Cislo P, Carson W. Metabolic syndrome comparison between olanzapine, aripiprazole, and placebo. Presented at the 2003 APA Annual Meeting, May 17-22, 2003; San Francisco, CA.
    • (2003) 2003 APA Annual Meeting
    • Casey, D.1    L'Italien, G.L.2    Waldeck, R.3    Cislo, P.4    Carson, W.5
  • 44
    • 0035897696 scopus 로고    scopus 로고
    • Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
    • Grundy SM, Decker D, Clark LT, et al. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
    • (2001) JAMA , vol.285 , pp. 2486-2497
    • Grundy, S.M.1    Decker, D.2    Clark, L.T.3
  • 45
    • 0000649068 scopus 로고    scopus 로고
    • Safety and tolerability meta-analysis of aripiprazole in schizophrenia
    • Stock E, Marder SR, Saha AR, et al. Safety and tolerability meta-analysis of aripiprazole in schizophrenia. Int J Neuropsychopharmacol 2002a; 5(Suppl 1):S186.
    • (2002) Int J Neuropsychopharmacol , vol.5 , Issue.1 SUPPL.
    • Stock, E.1    Marder, S.R.2    Saha, A.R.3
  • 46
    • 0000649072 scopus 로고    scopus 로고
    • Meta-analysis of cardiac safety with aripiprazole
    • Stock E, Marder SR, Saha AR, et al. Meta-analysis of cardiac safety with aripiprazole. Int J Neuropsychopharmacol 2002b; 5(Suppl 1):S186.
    • (2002) Int J Neuropsychopharmacol , vol.5 , Issue.1 SUPPL.
    • Stock, E.1    Marder, S.R.2    Saha, A.R.3
  • 47
    • 0021346160 scopus 로고
    • Orthostatic Hypotension II. Clinical diagnosis, testing, and treatment
    • Schatz IJ: Orthostatic Hypotension II. Clinical diagnosis, testing, and treatment. Arch Intern Med 1984; 144:1037-1041.
    • (1984) Arch Intern Med , vol.144 , pp. 1037-1041
    • Schatz, I.J.1
  • 48
    • 0023119548 scopus 로고
    • Management of anti-depressant-induced side effects. A practical guide for the clinician
    • Pollack MH, Rosenbaum JF: Management of anti-depressant-induced side effects. A practical guide for the clinician. J Clinical Psychiatry 1987; 48:3-8.
    • (1987) J Clinical Psychiatry , vol.48 , pp. 3-8
    • Pollack, M.H.1    Rosenbaum, J.F.2
  • 50
    • 4644346619 scopus 로고    scopus 로고
    • Safety and tolerability of aripiprazole in elderly patients with psychosis of Alzheimer's dementia: A pooled analysis
    • February 21-24, Baltimore, MD
    • Kujawa MJ and Bristol Meyers Squibb. Safety and tolerability of aripiprazole in elderly patients with psychosis of Alzheimer's dementia: A pooled analysis. Presented at 17 Annual meeting of the American Association of Geriatric Psychiatry, February 21-24, 2004; Baltimore, MD.
    • (2004) 17 Annual Meeting of the American Association of Geriatric Psychiatry
    • Kujawa, M.J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.